Home › Patient Participation › NCT05732779

Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients

Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients: Enhancing Technological Innovation and Strengthening the Role of Small Businesses in Meeting Needs of Adolescent Organ Transplant

Who can join

Ages 10 to 21 · All sexes

Inclusion Criteria:

* Eligible participants are 10-21 years of age
* Have received a heart transplant and are followed participating pediatric heart transplant centers
* English-speaking or Spanish-speaking
* Own a smart-phone or have access to the mobile app through other devices
* Are willing to receive information through it
* Have a MLVI score of greater than 2.0 over the last year

Exclusion Criteria:

• Those with cognitive impairments will not be eligible for enrollment due to inability to provide informed assent

About the study

We will conduct a two-group randomized controlled trial to examine the eMocha DOT intervention with pediatric HT recipients.In this population, medication nonadherence remains a primary cause of late acute rejection (LAR) episodes, increased number of hospitalizations, graft failure, and patient mortality. Herein, we propose an innovative approach to promote medication adherence and improve patient and graft outcomes.

What is being tested

• DOT intervention (other)

Sponsor: University of Florida · Participants: 100 · Started: Oct 1, 2024

Contact the study team

• Dipankar Gupta, MD · Phone: 352-273-5422
• Dalia Lopez-Colon, PhD · Phone: 352-281-6723

Official record on ClinicalTrials.gov — NCT05732779

Locations in the U.S.

Conditions

• Patient Participation

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.